Stay updated on Ublituximab in RMS: Clinical Trial

Sign up to get notified when there's something new on the Ublituximab in RMS: Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Ublituximab in RMS: Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    Added Hartung et al. 'Efficacy of Ublituximab in People with Highly Active Relapsing Multiple Sclerosis' (Neurol Ther, 2026; online ahead of print). Updated page revision to v3.4.3 (replacing v3.4.2).
    Difference
    0.1%
    Check dated 2026-03-12T03:28:50.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    19 days ago
    No Change Detected
  4. Check
    33 days ago
    Change Detected
    Summary
    Revision: v3.4.2 added; previous notice about government funding lapse (v3.4.1) removed. These changes affect only site maintenance and operate-status messaging, not trial data, eligibility, or study results. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-11T14:31:41.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    Funding-status notice appears at the top of the page and the site revision updated to v3.4.1, replacing the previous v3.4.0.
    Difference
    0.4%
    Check dated 2026-02-04T10:38:21.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    UI and metadata updates were made: a glossary display option was added, and new labels 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data' were introduced, along with a revision identifier 'v3.4.0'. The previous labels 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4' were removed.
    Difference
    0.2%
    Check dated 2026-01-28T06:38:29.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    The page footer shows Revision: v3.3.4, replacing Revision: v3.3.3.
    Difference
    0.1%
    Check dated 2026-01-14T02:36:28.000Z thumbnail image
  8. Check
    83 days ago
    Change Detected
    Summary
    A consolidated 'Locations' section lists participating states (Arizona, Colorado, Florida, Kentucky, Missouri, Nevada, New Jersey, New Mexico, New York, Ohio, Pennsylvania, Texas, Washington) and the prior state-specific location subsections were removed, restructuring how trial sites are presented.
    Difference
    1%
    Check dated 2025-12-23T17:25:02.000Z thumbnail image

Stay in the know with updates to Ublituximab in RMS: Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Ublituximab in RMS: Clinical Trial page.